Table 1.
Parameter estimates and bootstrap analysis for the final model for SG
| Parameter | Final model estimate (%RSE) | Bootstrap analysis median value (95% CI) |
|---|---|---|
| CLSG, L/h | 0.133 (1.01) | 0.133 (0.131 to 0.137) |
| QSG, L/h | 0.006 (3.07) | 0.006 (0.005 to 0.006) |
| V1SG, L | 2.770 (0.87) | 2.770 (2.72 to 2.82) |
| V2SG, L | 0.908 (3.29) | 0.906 (0.852 to 0.974) |
| IIV variance for CLSGa | 0.011 (14.50) | 0.011 (0.008 to 0.016) |
| Weight exponent on CLSG and QSG | 0.508 (6.77) | 0.503 (0.428 to 0.567) |
| Weight exponent on V1SG and V2SG | 0.532 (6.28) | 0.526 (0.463 to 0.593) |
| Baseline serum albumin exponent on CLSG | –0.355 (14.90) | –0.355 (–0.467 to –0.256) |
| Time after last dose on RUV | 0.005 (19.10) | 0.005 (0.004 to 0.008) |
| RUV SD on log SG | 0.204 (5.93) | 0.202 (0.182 to 0.23) |
%RSE relative standard error in percent, CI confidence interval, CLSG clearance, IIV interindividual variability, QSG intercompartmental clearance, RUV residual unexplained variability, SD standard deviation, SG sacituzumab govitecan, V1SG central volume of distribution, V2SG peripheral volume of distribution
aShrinkage for IIV variance for CLSG was 25.8%